Why the study?
Heart failure constitutes a significant clinical problem and healthcare burden, prompting investigation of novel device interventions to improve clinical outcomes.
This review highlights the potential of novel therapeutic devices targeting autonomic imbalance, respiratory disturbances, and decongestion in heart failure management, emphasizing the need for further clinical evidence.
Device-based autonomic modulation in HF remains investigational; leaves open its role pending randomized outcome trials.
Heart failure (HF) constitutes a significant clinical problem and is associated with a sizeable burden for the healthcare system. Numerous novel techniques, including device interventions, are investigated to improve clinical outcome. A review of the most notable currently studied devices targeting pathophysiological processes in HF was performed. Interventions regarding autonomic nervous system imbalance, i.e., baroreflex activation therapy; vagus, splanchnic and cardiopulmonary nerves modulation; respiratory disturbances, i.e., phrenic nerve stimulation and synchronized diaphragmatic therapy; decongestion management, i.e., the Reprieve system, transcatheter renal venous decongestion system, Doraya, preCardia, WhiteSwell and Aquapass, are presented. Each segment is divided into subsections: potential pathophysiological target, existing evidence and weaknesses or unexplained issues. Novel therapeutic devices represent great potential in HF therapy management; however, further evidence is necessary to fully evaluate their utility.
No takes yet. Share an insight, caveat, or question.
Guzik et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: